Summit Partners Public Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Summit Partners Public Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-121,117	Closed	-$11.8M	–	136
2023 Q1	$11.8M	Sell	121,117 -74,549	-38%	-$7.73M	0.48%	66
2022 Q4	$20.2M	Buy	195,666 +195,357	+63,222%	+$18.3M	1.28%	35
2022 Q3	$26K	Buy	+309	New	+$27.5K	﹤0.01%	114

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Summit Partners Public Asset Management's BMRN Position: Q2 2023 in Review

Summit Partners Public Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 121,117 shares — an estimated $11.8M sold.

Summit Partners Public Asset Management first reported a position in BMRN in Q3 2022 and held it in 3 quarters. The position peaked at $20.2M in Q4 2022. 557 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Summit Partners Public Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Summit Partners Public Asset Management sold 121,117 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $11.8M.
Summit Partners Public Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2022 and held it in 3 quarters.
Summit Partners Public Asset Management's BioMarin Pharmaceuticals position peaked at $20.2M in Q4 2022.
557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Summit Partners Public Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.